Sana Biotechnology: Promising Treatments for Cancer and Autoimmune Diseases

lunes, 19 de enero de 2026, 7:41 am ET1 min de lectura
SANA--

Sana Biotechnology is a biotech company developing therapies for cancer and autoimmune diseases using ex vivo hypoimmune therapy and in vivo fusogen-based delivery systems. Their ex vivo platform aims to improve treatment outcomes and reduce side effects. Investors should be cautious and wait for dips in the stock, despite promising T1D science.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios